Glucose fluctuations aggravate myocardial fibrosis via activating the CaMKII/Stat3 signaling in type 2 diabtetes
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Glucose fluctuations aggravate myocardial fibrosis via activating the CaMKII/Stat3 signaling in type 2 diabtetes
Authors
Keywords
-
Journal
Diabetology & Metabolic Syndrome
Volume 15, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-28
DOI
10.1186/s13098-023-01197-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease
- (2023) Simon Lebek et al. SCIENCE
- Cardiac-specific BACH1 ablation attenuates pathological cardiac hypertrophy by inhibiting the Ang II type 1 receptor expression and the Ca2+/CaMKII pathway
- (2023) Xiangxiang Wei et al. CARDIOVASCULAR RESEARCH
- Metformin suppresses cardiac fibroblast proliferation under high-glucose conditions via regulating the mitochondrial complex I protein Grim-19 involved in the Sirt1/Stat3 signaling pathway
- (2023) Yongguang Li et al. FREE RADICAL BIOLOGY AND MEDICINE
- CaMKII regulates the proteins TPM1 and MYOM2 and promotes diacetylmorphine-induced abnormal cardiac rhythms
- (2023) Min Ji et al. Scientific Reports
- Higher glucose fluctuation is associated with a higher risk of cardiovascular disease: Insights from pooled results among patients with diabetes
- (2023) Feng Li et al. Journal of Diabetes
- Visit-to-Visit Variability in Fasting Blood Glucose Predicts the New-Onset Heart Failure: Results From Two Large Chinese Cohorts
- (2023) Yueying Wang et al. CURRENT PROBLEMS IN CARDIOLOGY
- Elevated MCU Expression by CaMKIIδB Limits Pathological Cardiac Remodeling
- (2022) Pei Wang et al. CIRCULATION
- DYRK1B-STAT3 Drives Cardiac Hypertrophy and Heart Failure by Impairing Mitochondrial Bioenergetics
- (2022) Lingfang Zhuang et al. CIRCULATION
- Novel CaMKII-δ Inhibitor Hesperadin Exerts Dual Functions to Ameliorate Cardiac Ischemia/Reperfusion Injury and Inhibit Tumor Growth
- (2022) Junxia Zhang et al. CIRCULATION
- Pirfenidone attenuates cardiac hypertrophy against isoproterenol by inhibiting activation of the janus tyrosine kinase-2/signal transducer and activator of transcription 3 (JAK-2/STAT3) signaling pathway
- (2022) Zhenhuan Chen et al. Bioengineered
- The functions of Ca2+/calmodulin-dependent protein kinase II (CaMKII) in diabetes progression
- (2022) Khaled Benchoula et al. Journal of Cell Communication and Signaling
- Glucose Fluctuations Aggravate Myocardial Fibrosis via the Nuclear Factor-κB-Mediated Nucleotide-Binding Oligomerization Domain-Like Receptor Protein 3 Inflammasome Activation
- (2022) Zhen-Ye Zhang et al. Frontiers in Cardiovascular Medicine
- CaMKII as a Therapeutic Target in Cardiovascular Disease
- (2022) Oscar E. Reyes Gaido et al. Annual Review of Pharmacology and Toxicology
- RGS11-CaMKII complex mediated redox control attenuates chemotherapy-induced cardiac fibrosis
- (2022) Kiran Das et al. Redox Biology
- Glycaemic variability and risk of adverse cardiovascular events in acute coronary syndrome
- (2022) Lei Zhang et al. Diabetes & Vascular Disease Research
- Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
- (2022) Tadej Battelino et al. Lancet Diabetes & Endocrinology
- Alleviation of Inflammation and Oxidative Stress in Pressure Overload-Induced Cardiac Remodeling and Heart Failure via IL-6/STAT3 Inhibition by Raloxifene
- (2021) Shengqi Huo et al. Oxidative Medicine and Cellular Longevity
- Significant abnormal glycemic variability increased the risk for arrhythmias in elderly type 2 diabetic patients
- (2021) Jianbo Zhang et al. BMC Endocrine Disorders
- Glucose fluctuation accelerates cardiac injury of diabetic mice via sodium-dependent glucose cotransporter 1 (SGLT1)
- (2021) Weihua Wu et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- RIPK3-Mediated Necroptosis in Diabetic Cardiomyopathy Requires CaMKII Activation
- (2021) Yun Chen et al. Oxidative Medicine and Cellular Longevity
- CaMKII inhibitor KN‐93 impaired angiogenesis and aggravated cardiac remodelling and heart failure via inhibiting NOX2/mtROS/p‐VEGFR2 and STAT3 pathways
- (2021) Yajuan Ni et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Glycaemic management in diabetes: old and new approaches
- (2021) Antonio Ceriello et al. Lancet Diabetes & Endocrinology
- Enhanced CaMKII-Dependent Late I Na Induces Atrial Proarrhythmic Activity in Patients With Sleep-Disordered Breathing
- (2020) Simon Lebek et al. CIRCULATION RESEARCH
- Hyperglycemia Acutely Increases Cytosolic Reactive Oxygen Species via O -linked GlcNAcylation and CaMKII Activation in Mouse Ventricular Myocytes
- (2020) Shan Lu et al. CIRCULATION RESEARCH
- CaMKII signaling in heart diseases: Emerging role in diabetic cardiomyopathy
- (2019) Bence Hegyi et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Inhibition of EGFR-STAT3 attenuates cardiomyopathy in streptozotocin-induced type 1 diabetes
- (2019) Wu Luo et al. JOURNAL OF ENDOCRINOLOGY
- βIV-Spectrin regulates STAT3 targeting to tune cardiac response to pressure overload
- (2018) Sathya D. Unudurthi et al. JOURNAL OF CLINICAL INVESTIGATION
- Cardiac STAT3 Deficiency Impairs Contractility and Metabolic Homeostasis in Hypertension
- (2016) Raffaele Altara et al. Frontiers in Pharmacology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search